Announcements Trials
Browse Landscape

Phase

Phase 2 29Phase 3 18Phase NA 3Phase 1 3Phase 4 2Phase EARLY_PHASE1 1Phase 2/3 1Phase 1/2 1

Status

Completed 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3Polycystic Ovary Syndrome 1Metastatic Neuroendocrine Prostate Cancer 1Metastatic Castration-Resistant Prostate Cancer 1Kallmann Syndrome 1Hypogonadism 1Hyperprolactinemia 1Breast Neoplasms 1

Interventions

Docetaxel 43enzalutamide 31Prednisone 25Abiraterone Acetate 24Magnetic Resonance Spectroscopy 18abiraterone 15pembrolizumab 14bicalutamide 14Radiotherapy 14Cyclophosphamide 13darolutamide 12Leuprolide 12Goserelin 12apalutamide 10Ipilimumab 10olaparib 9Specimen Handling 9Radiosurgery 9Radiation 9Injections 9Biopsy 9Pluvicto 8Paclitaxel 8Radiotherapy, Intensity-Modulated 7Carboplatin 7sargramostim 6fludarabine 6cabazitaxel 6Sirolimus 6Nivolumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Prostatic Neoplasms × Gonadotropin-Releasing Hormone × Clear all
NCT05999968 2026-03-05

Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

Eli Lilly and Company

Phase 1 Completed
10 enrolled
Genitourinary

Prostatic Neoplasms

NCT01420250 2025-05-15

Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer

Thomas Jefferson University

Phase 1 Completed
20 enrolled
Genitourinary

Prostatic Neoplasms

NCT00099086 2024-01-31

Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer

Medical University of South Carolina

Phase 1 Completed
20 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡